AIM
RPRX

Acrospire Investment Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Acrospire Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-24,881
Closed -$30K – 2894
2017
Q1 		$30K Buy
24,881
+1,704
+7% +$2.13K 0.02% 1365
2016
Q4 		$31K Buy
23,177
+3,810
+20% +$6.63K 0.01% 1628
2016
Q3 		$40K Buy
19,367
+4,248
+28% +$8.4K 0.03% 1202
2016
Q2 		$24K Buy
+15,119
New +$29K 0.02% 1477

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's RPRX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2017, closing a stake of 24,881 shares — an estimated $30K sold.

Acrospire Investment Management first reported a position in RPRX in Q2 2016 and held it in 4 quarters. The position peaked at $40K in Q3 2016. 29 funds tracked by Wall St. Rank hold RPRX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Repros Therapeutics Inc. position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 24,881 Repros Therapeutics Inc. shares in Q2 2017, an estimated $30K.
  • Acrospire Investment Management first reported a position in Repros Therapeutics Inc. in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Repros Therapeutics Inc. position peaked at $40K in Q3 2016.
  • 29 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.